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The aim of this study is to investigate postoperative complications, mortality rates, and to
determine the factors affecting mortality on the patients receiving warfarin therapy
preoperatively, as well as comparing the results obtained from emergency and elective
surgeries. Surgical outcomes of 61 patients on long-term oral anticoagulation with
warfarin who underwent surgery in our center were retrospectively reviewed over an 8-
year period. Thirty-three (54.1%) patients were female, with a mean age of 53 years.
Mitral valve replacement (62.3%) was the most frequent indication for chronic
anticoagulation therapy. Twelve out of 61 (19.2%) patients underwent emergency surgery;
59 (96.7%) operations were classified as major surgery. We did not observe any
thromboembolic events on patients receiving our bridging therapy protocol. Cardiopul-
monary dysfunction (CPD; 19.7%) and hemorrhage (16.4%) were the most encountered
postoperative complications. Presence of CPD, bleeding, endocarditis, and mortality
were statistically significant for emergency surgeries when compared with the results
obtained from elective surgeries. There were 5 (8.2%) deaths observed during follow-up.
It was found that advanced age, prolonged duration of operations, and presence of CPD
had a statistically significant effect on mortality (P , 0.05). The patients receiving oral
anticoagulant had high postoperative complication and mortality rates. This case was
more evident in emergency surgeries. It is recommendable that as mortality is more
apparent in the patients who undergo emergency surgeries—being older, having long
duration of operations as well as CPD. Therefore during the postoperative follow-up
process, the patients should be closely monitored.
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Thromboembolism is a major global healthconcern contributing to more than 0.5 million
deaths in Europe and up to 300,000 deaths in the
United States each year.1 Versatile arrays of antico-
agulant and/or anti-aggregant agents are available.
They are used to treat and prevent thrombosis
occurring as a result of venous stasis, valvular heart
disease, prosthetic valves, atrial fibrillation, or
myocardial infarction. After using these medica-
tions, patients who require elective or emergency
surgery represent a specific population; moreover,
they are prone to developing either excessive
bleeding or thrombosis.
The annual incidence of major bleeding as a
result of oral anticoagulant (OAC) use is reported
between 2 and 5%.2 Patients on OAC may require
elective or sometimes emergency surgical or inva-
sive procedures. There is no consensus on standard
protocol to follow for those who require perioper-
ative management.3
In the current literature, there are limited num-
bers of studies regarding the discussions about the
operations in general surgery patient population
receiving warfarin treatments. In this retrospective
study, our aim was to document the complications
and outcomes of general surgical procedures imple-
mented on patients receiving warfarin. Along with
the comparison of the emergency and elective
surgeries performed, we also aimed to determine
the factors affecting mortality.
Patients and Methods
Data collection
The study was conducted according to the tenets of
the Declaration of Helsinki on Biomedical Research
involving Human Subjects. This retrospective clin-
ical study was performed at Baskent University,
Department of General Surgery after obtaining the
approval of the university ethical committee (KA13/
129). This is a retrospective review of patients on
long-term anticoagulation with warfarin who un-
derwent surgery in our department over a period of
8 years: from January 2006 to December 2013.
Demographic data, mode of presentation, American
Society of Anesthesiologists (ASA) score, indication
and duration of OAC therapy, comorbidities, inter-
national normalized ratio (INR), prothrombin time
(PT) and activated partial thromboplastin time
(aPTT) values, surgical technique, and duration of
procedures were collected retrospectively from
charts and computerized medical records. Treat-
ment outcomes, mortality rates, thromboembolic or
bleeding events observed, and length of hospital
stay were also recorded.
Not only were the patients receiving no warfarin
prior to their procedure excluded, but we also
excluded those who were to have their warfarin
discontinued immediately postoperatively. We also
excluded patients who received anticoagulant
agents other than warfarin. Besides assuring the
conditions stated above, the patients having deep
venous thrombosis and pulmonary embolism were
also excluded.
Perioperative bridging anticoagulation therapy
In patients who were undergoing elective surgical
procedures, warfarin was discontinued 5 days prior
to surgery (that is, the last dose was given 6 days
prior to the day of surgery). Patients were admitted
to an inpatient clinic 3 days before surgery. Bridging
therapy with unfractionated heparin (UFH) was
started when INR levels dropped below 2.0. A level
of INR of 1.5 or below was considered suitable for
surgery. A final PT and INR level was obtained for
every patient on the morning of surgery. If the
patient still had an increased INR (1.8 or above) after
3 days, vitamin K (oral preparation of 1–2.5 mg) was
given. Unfractionated heparin was stopped 6 hours
before surgery. However, if the patient required
emergency surgery, the bridging process had to be
expedited by holding the warfarin and administer-
ing 10 mg of vitamin K via intravenous infusion
over 15 to 30 minutes. The next step was to
administer 15 mL of fresh-frozen plasma (FFP) per
kilogram of patient body weight.
If no bleeding was suspected or observed, UFH
was started again 6 hours after surgery. Complete
blood count and INR levels were obtained daily
during the postoperative period. Follow-up INR
levels were obtained once every 3 days after the
target level of INR was reached. When oral intake
was allowed, OAC was started along with UFH
until the target level of INR was reached. Unfrac-
tionated heparin was then discontinued and pa-
tients were discharged when their general medical
condition was satisfactory. Levels of INR were
obtained monthly (28 6 4 days) when there were
no additional problems. For the patients with a
history of previous heart valve replacement, antibi-
otic prophylaxis was provided with sulbactam þ
ampicillin (4 g) and gentamycin sulfate (120 mg)
during the induction of anesthesia.
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Outcome variables
For the purposes of the study, major hemorrhage
was defined as: overt bleeding leading to a more
than 3 g dL1 drop in hemoglobin levels; transfusion
of more than 2 units of packed red blood cells or
whole blood; or any intracranial, retroperitoneal, or
intraocular bleeding that required surgical interven-
tion or resulted in death. All other bleeding events
that did not meet the criteria for major bleeding
were classified as minor in accordance with previ-
ous literature.4
Major surgery was described as intervention
lasting longer than 45 minutes or orthopedic,
cardiothoracic, vascular surgical procedures. All
other surgical procedures were defined as minor
surgery, similar with the earlier publications.5
Emergency surgery was defined as nonelective
surgery performed when the patients’ life or well-
being was in direct jeopardy.
Subgroup analysis was performed to determine
the incidence of major bleeding by the extent of the
procedure (minor or major surgery). Cardiopulmo-
nary and thromboembolic events were taken into
consideration when they occurred at any time
during the study period (from the cessation of
warfarin therapy 5 days prior to surgery until 28
days after the INR value was within the therapeutic
range).
We define ‘‘cardiopulmonary dysfunction’’ in
accordance with previous studies and with the
European Association for Cardio-thoracic Surgery/
European Society of Thoracic Surgeons thoracic
surgery database as postoperative pneumonia;
postoperative respiratory failure (requiring mechan-
ical ventilation for more than 48 hours); pulmonary
edema, atelectasis or hypoxemia, serious postoper-
ative arrhythmias; acute coronary syndromes and
cardiac failure.6–8 Postoperative morbidity and
mortality were considered as those occurring within
30 days postoperatively or for a longer period when
the patient was still in hospital follow-up.6–8
Statistical analysis
Data were collected and analyzed digitally using a
program for statistics (SPSS, version 17.0; SPSS, Inc.,
Chicago, IL, USA). For each continuous variable,
normality was checked by Kolmogorov Smirnov
and Shapiro-Wilk tests and by histograms. Compar-
isons between groups were applied using Mann
Whitney U test when the data were not normally
distributed. The categorical variables between the
groups were analyzed by using the v2 test or
Fisher’s exact test. Factors associated with a P value
of less than 0.05 in univariate analysis were further
evaluated in a multiple regression analysis. A
multiple logistic regression analysis was used to
determine the associations between mortality or
morbidity and other measurements that were
classified as dependent variables. Values of P ,
0.05 were considered statistically significant.
Results
A total of 61 patients on long-term warfarin were
included in the study. The demographics, perioper-
ative clinical features, and distribution of indications
for OAC use of 61 anticoagulated patients are
detailed in Table 1. A history of mitral valve
replacement (MVR) was the most common indica-
tion for using warfarin preoperatively, followed by
aortic valve replacement (Table 1). At least more
than 1 disease state requiring OAC use was present
in 36 patients (59%). Comorbidities other than
reason for OAC use—including diabetes mellitus
and hypertension—were present in 63.9% of pa-
tients (Table 1). Four of the patients (6.5%) received
vitamin K (INR  1.8) pre-operatively.
Cholecystectomy was the most frequently per-
formed primary procedure (n ¼ 36; 59%). Twelve
patients had also synchronous secondary operations
that were all elective. Among all operations per-
formed, 49 (80.3%) were elective and 12 (19.7%)
were emergency (Table 2). The patients receiving
emergency operations were not optional. Fifty nine
(96.7%) operations were classified as major and 2
(3.3%) were as minor. Intraoperatively drains were
placed in 35 (57.4%) patients as a part of surgical
procedures.
Cardiopulmonary dysfunction (CPD) and bleed-
ing were the most frequently encountered postop-
erative complications more pronounced in
emergency cases (Table 3). Major bleeding was
encountered in 7 (11.5%) patients while 3 (4.9%) of
the patients had minor bleeding. In the analysis of
the patients having postoperative bleeding, it was
found that there was statistically significant differ-
ences regarding the duration of operations (P ¼
0.012). Moreover, it was also found that the
difference regarding the length of hospital stay
was statistically significant (P ¼ 0.001). Seven
patients with CPD had also bleeding. Five of these
bleeding events were major and 2 were minor.
Mortality was observed in 5 patients (Table 3). All
these patients who died developed major bleeding
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and CPD. It was determined that the high preoper-
ative INR levels (P ¼ 0.003), PT levels (P ¼ 0.004),
and the duration of operations (P ¼ 0.004) were
individually significant risk factors affecting CPD in
analysis of univariate. As for in analysis of multi-
variate, it was also determined that the duration of
operations was an individually significant risk
factor affecting CPD (1.1%; 95% CI, 1.01–1.02; P ¼
0.033). All the bleeding episodes were encountered
before patients were discharged. The rate of blood
transfusion was 16.4%. After all, we did not observe
any thromboembolic events.
Five out of 7 patients who had major bleeding
were managed conservatively (erythrocyte suspen-
sion, fresh frozen plasma and vitamin K replace-
ment). The remaining 2 patients were re-operated on
for hemostasis. These patients were initially operat-
ed for pancreas carcinoma (pancreaticoduodenecto-
my) and sigmoid colon perforation (Colon resection
and Hartmann’s procedure). Although hemostasis
was restored during the revision surgery, both
patients died.
Two patients who were operated in emergency
settings developed major bleeding. These 2 patients
also developed endocarditis following surgery. One
patient died due to severe sepsis on postoperative
day 13. This patient had received 18 units of
erythrocyte suspension prior to surgery to treat
upper gastrointestinal bleeding and an additional 7
units after the surgery. The second patient also died
due to sepsis on day 12 after the surgery. It was
found that in the analysis of univariate, demograph-
ic and clinical data were not determined as a risk
factor regarding the development of endocarditis.
Two of the emergency procedures were appen-
dectomy (Table 2) and these patients’ INR values
were 1.9 and 1.6. When decision for surgical
Table 1 Perioperative demographics, clinical features, and distribution
of indications for OAC use among patients
Variable
Total, n ¼ 61 (%) or
mean 6 SD
Mean age, y 55 6 13
Sex
Female 33 (54.1)
Male 28 (45.9)
Mean body mass index 27 6 5
Indications for taking warfarin
Mitral valve replacement 38 (62.3)
Aortic valve replacement 15 (24.6)
Atrial fibrillation 7 (11.5)
Coronary bypass grafting 1 (1.6)
Comorbidities
Present 39 (63.9)
Absent 22 (36.1)
ASA classification
II 20 (32.8)
III 41 (67.2)
Preoperative INR value 1.3 6 0.5
Preoperative aPTT value 38 6 13
Preoperative PT 16 6 5
Mean duration of procedure, min 97 6 67
Length of stay, days 9 6 6
Pre-operative 4 6 3
Postoperative 6 6 4
Table 2 Surgical treatment procedures in patients receiving warfarin
All patients (n ¼ 61) Types of surgical procedure, (n ¼ 61) Synchronous secondary operations, (n ¼ 12)
Elective surgery, 49 (80.3%) Hepatobiliary pancreatic surgery (35)
 Cholecystectomy (34)*
 Pancreaticoduodenectomy (1)
Hernia (7)
Thyroid and parathyroid (3)
Proctological surgery (2)
Colorectal surgery (2)
Hernia (4)
Breast surgery (3)
Upper gastrointestinal system surgery (2)
Hepatobiliary pancreatic surgery (2)
 Choledocotomy (1)
 Cholecystectomy (1)
Thyroid and parathyroid surgery (1)
Emergency surgery, 12 (19.7%) Upper gastrointestinal system (5)
 Truncal vagotomy and pyloroplasty (2)
 Subtotal small bowel resection (2)
 Primary repair for bleeding ulcer (1)
Colorectal surgery (3)
 Appendectomy (2)
 Sigmoid colon resection and colostomy (1)
Hernia (3)
 Strangulated incisional hernia (2)
 Strangulated femoral hernia (1)
Hepatobiliary pancreatic surgery (1)
 Cholecystectomy (1)
* Laparoscopic cholecystectomy (n¼ 24).
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operation was given, average 3.5 hours passed from
decision until operation time for bridging therapy.
The first patient received 2 units of FFP and the
other patient received 1 unit of FFP; and in the
postoperative period, none of the patients bled.
In terms of bleeding rates, comparing the elective
group with the emergency treatment group, whom
were prepared quickly and treated, the rate of the
emergency treatment group was higher and statis-
tically more significant (P ¼ 0.008). Therefore, the
emergency group was compared again. Twelve
patients in the emergency group were given a
median of 2 units of FFP (range: 1–3 units) and
they were operated after a median of 2 hours (range:
1–6 hours). Five of these patients (41.7%) bled. The
effect of the amount FFP administered and the delay
for the decision until operation time to perform
bridging therapy on postoperative bleeding compli-
cations were compared as subgroups, the result of
which was not statistically significant (P . 0.05).
Median level of INR before the operation was 1.5
(range: 1.1–4.1) for the patients who bled. Two of
those patients were operated on again. The patient
who underwent a Whipple procedure was operated
on due to major vessel injury. The other patient for
whom ostomy was performed after sigmoid colon
perforation, there was not a significant source of
bleeding and we interpreted the situation as it was
related to impaired coagulation parameters because
of sepsis. In 5 out of 8 patients who were not re-
operated were found to have disorder of coagula-
tion parameters because of sepsis, and the other 3
patients were seen to have postoperative hemor-
rhage because of gastrointestinal bleeding.
We found a statistically significant result as to the
comparison of the complications of the patients
undergoing emergency and elective surgeries; CPD,
bleeding, and endocarditis rates were higher in the
patients undergoing emergency surgeries (Table 3).
Seven out of 10 patients (58.3%) who had bleeding
had CPD. In a similar way, the mortality rate was
higher in a statistically significant manner for the
patients undergoing emergency surgeries (Table 3).
Mean age, preoperative INR, and PT values were
significantly higher in the patients who underwent
emergency surgery as well as experienced a longer
postoperative hospital stay (Table 3).
Patients who underwent synchronous surgery
were compared with those patients having no
synchronous operation in terms of bleeding, mor-
tality, and CPD. There were no statistically signifi-
cant differences between the 2 groups, in terms of
bleeding, mortality, and CPD (respectively, P¼ 0.67,
0.69, 0.25). When all complications were evaluated,
there was no statistical difference (P ¼ 0.49).
In the analysis of the patients with mortality, age
(P ¼ 0.003), and the duration of operations (P ¼
0.003) were statistically significant (Table 4). In
analysis of multivariate, it was determined that
there was not any individual risk factors regarding
the mortality rates. However, when it comes to the
individual analysis of the complications affecting
the mortality rates, CPD (P¼ 0.001) had a significant
effect on the mortality. It was also found that
endocarditis (P¼ 0.158) and postoperative bleeding
(P ¼ 0.185) had no significant effect on mortality.
Discussion
Patients who are on oral anticoagulants because
they have atrial fibrillation, mechanical heart valves,
myocardial infarction, and pulmonary embolism are
at a high risk for arterial or venous thromboembo-
lism.9 Cessation of OAC therapy may be required in
patients who are in need of elective or emergency
surgery and other invasive procedures. These
patients need some sort of bridging anticoagulant
therapy and may require hospitalization prior to
Table 3 Summary of outcome events of follow-up and comparison of variable subgroups for emergency versus elective surgery
Postoperative complications and variable Emergency, n (%) or mean 6 SD Elective, n (%) or mean 6 SD P value
Mean age, y* 63.2 6 13.9 53.1 6 13.3 0.023
Preoperative INR* 1.77 6 0.8 1.2 6 0.1 0.004
Preoperative PT* 20.7 6 9.8 15 6 2.1 0.006
Duration of procedure, min 125 6 97 90 6 57.7 0.11
Cardiopulmonary dysfunction* 7/12 (58.3) 5/49 (10.2) 0.001
Bleeding* 5/12 (41.7) 5/49 (10.2) 0.008
Endocarditis* 2/12 (16.6) 0 0.004
Mortality* 3/12 (25) 2/49 (4.1) 0.018
Length of stay, d 14.8 6 10.3 8.6 6 4.5 0.085
Postoperative length of stay, d* 10.2 6 6.4 4.8 6 3.6 0.004
* Statistically significant factors (P , 0.05).
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their planned procedure. In Europe and North
America, it is reported that nearly 4 million patients
use OAC and each year 10% of these require
cessation of OAC therapy for various reasons.10
Unfortunately, there is no consensus regarding the
protocol on how to conduct bridging anticoagula-
tion for these patients.11 Major reasons for this lack
of standardization are the large span of indications,
comorbidities, procedures, and different heparin
types available. It is the physician’s responsibility
to balance risk of bleeding against risk of thrombo-
embolic complications for each individual patient.
As warfarin is the most commonly used OAC,
bridging anticoagulation is usually conducted by
discontinuing warfarin and administering UFH or
low molecular weight heparin (LMWH).12–18 Both
agents have advantages and disadvantag-
es.4,5,14,15,19–22 There are several studies stating that
LMWH is safer and more efficient than UFH. On the
other hand, a comparative study enrolling 901
patients found no difference between UFH and
LMWH in terms of thromboembolism, major bleed-
ing, and death ratios.5 At our center, UFH is
preferred for bridging anticoagulation therapy
since, it has a shorter half-life than LMWH, and its
effects may be monitored and reversed much easier.
Many of our patients were treated with OAC due
to previous MVR and aortic valve replacement, in a
similar manner with the literature.23 Again, most of
our patients were in the category of ASA III and had
comorbid diseases. Of the surgical procedures,
96.7% were in major surgical categories. In our
experience, laparoscopic cholecystectomy was the
most common surgical procedure (n ¼ 24; 39.3%).
Bleeding was encountered in only 2 of the patients
who had laparoscopic cholecystectomy (18.3%). The
largest series involving laparoscopic cholecystecto-
my in this group of anticoagulated patients included
44 patients.24 Enoxaparin was used for bridge
anticoagulation in that study. Postoperative bleed-
ing was observed in 11 (25%) of 44 patients.24
Thromboembolism cases have not been reported in
the same study. Again, bleeding was not reported in
33 patients on warfarin undergoing elective laparo-
scopic cholecystectomy and was given bridging
therapy with LMWH.24 In our study, the likelihood
of bleeding seems to be quite high in patients on
warfarin undergoing elective laparoscopic cholecys-
tectomy compared with mentioned former series.
We did not find thromboembolism in these patients.
There are few related studies and consensus in the
literature in this ratio. Again, bridging therapy
protocol to be applied in these patients is still
unclear. Larger prospective clinical studies are
needed for this condition to be set forth more
clearly. Different rates of major hemorrhage were
reported when the series of different branches of
surgical operations were evaluated.21–24 These rates
vary over a wide range of 0.7 to 27.5%.21–25 In the
same study, thromboembolism was reported in a
ratio of 0.4 to 3.6%.21–25 Although none of our
patients developed thromboembolism, the major
bleeding rate was 11.5% in our study.
Comorbid pathologies and presence of major
surgery are reported to be the independent risk
factors for bleeding.21–25 In our experience, major
bleeding was observed in 16.9% of 59 patients who
had major surgery and no bleeding was observed
in patients having minor surgery. However, our
study did not determine the effects of comorbid
diseases on bleeding. Unlike some other studies,
absence of different branches of surgical operations
(especially orthopedic and cardiac surgery) and
Table 4 Analysis of factors that may have an effect on mortality
Variable
Mortality
n (%) or mean 6 SD
Yes,
(n ¼ 5)
No,
(n ¼ 56) P value
Mean age,* y 72 6 6 53 6 13 0.003
Sex 1
Female 3 (60) 30 (53.6)
Male 2 (40) 26 (46.4)
Mean body mass index 28 6 5 27 6 5 0.733
Indications for taking warfarin 0.922
Mitral valve replacement 3 (60) 35 (62.5)
Aortic valve replacement 1 (20) 14 (25)
Atrial fibrillation 1 (20) 6 (10.7)
Coronary bypass grafting 0 (0) 1 (1.8)
Comorbidities 0.645
Present 4 (80) 35 (62.5)
Absent 1 (20) 21 (37.5)
ASA classification 0.162
II 0 (0) 20 (32.8)
III 5 (12.2) 36 (67.2)
Preoperative INR value 1.7 6 0.6 1.3 6 0.4 0.077
Preoperative aPTT value 34 6 4 38 6 14 0.482
Preoperative PT 19 6 5 16 6 5 0.168
Mean duration of
procedure,* min 180 6 118 90 6 56 0.003
Length of stay, d 14 6 13 9 6 5 0.136
Pre-operative 6 6 9 4 6 3 0.125
Postoperative 9 6 6 9 6 6 0.42
Postoperative complications
CPD* (12) 5 (100) 7 (12.5) 0.001
Bleeding (10) 2 (40) 8 (14.3) 0.185
Endocarditis (2) 1 (20) 1 (1.8) 0.158
* Statistically significant factors (P , 0.05).
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usage of heparin for bridging therapy may have
been the reason that thromboembolism was not
seen in our series.19–25 However, as we noted
earlier, larger prospective clinical studies are
needed for this situation to be demonstrated more
clearly. Duration of the surgery which was not
specified in previous studies was seen to be an
independent risk factor for bleeding in our study.
In addition, the duration of hospital stay in these
patients was found to be longer, as reported in
previous studies.23
Bleeding, endocarditis, CPD, and mortality was
found to be significantly higher in patients who
were operated on urgently. Again, levels of PT/
INR were significantly higher and hospital stay
was significantly longer for the emergency opera-
tion group than the group undergoing elective
surgery. These conditions were not evaluated in
previous studies. In a recent study, it has been
advised that in order to reduce the risk of bleeding,
warfarin needs to be stopped 5 days prior to
surgery and an INR level of 1.5 is desirable.26
However, the condition of the patient may not
permit optimization of the INR level as observed in
our emergency patients (n¼ 12) in whom 5 (41.7%)
had a bleeding episode postoperatively. Contrary
to our usual practice, we placed drains in many
patients (57.4%) in this series. Although drains are
not advised for standard intra-abdominal proce-
dures, in this group they may have important
practical value as we have detected postoperative
bleeding by monitoring the discharge from the
drains. As a practical measure, we recommend that
drains be placed in most patients in this category
for the early detection and management of postop-
erative bleeding. Endocarditis was detected in only
two patients those who had emergency surgery. We
did not find any independent risk factors for
endocarditis. Also, there were no data in previous
studies regarding endocarditis.
In our analysis, mortality was found to be
higher in elderly patients and in patients with
longer duration of surgery. In our study we did
not find any independent risk factors for mortal-
ity. However, we found that although CPD had an
effect on mortality rate, endocarditis, and bleeding
did not. We were unable to find any reviews about
this situation in previous studies. According to
our results, advanced patient age, prolonged
operation time and limitation in cardiopulmonary
reserve were shown to be effective on the
increased mortality. Although bleeding is common
with 40% since the result is not statistically
significant with P value of 0.185, it does not seem
that it has an effect on mortality whatsoever.
Under the strength of these results, we assume
that the mortality and morbidity of urgent
operations are higher due to the inability to
correct coagulation parameters adequately and
appropriately.
The largest restriction of our study is its retro-
spective nature. Most of the studies in literature deal
with heterogeneous patient series in terms of
various surgical specialties. In these studies, more
bleeding and thromboembolic complications were
evaluated as the most outstanding ones. However,
in our study CPD was observed as the most
common complication which is the only factor
having an effect on mortality rates. Although our
study still lacks patient homogeneity, to some
extent, is more specific than other studies in the
literature evaluating only general surgical opera-
tions. This situation is the second major restriction
of our study. We believe that this case can be
specified by means of additional multicenter pro-
spective trials.
Conclusion
As a result, invasive procedures performed in
patients on oral anticoagulants are always risky.
Surgery in patients on anticoagulation therapy
increases the risk of bleeding and mortality espe-
cially on emergent cases. Although bleeding is
common, we determined that it had no effects on
mortality. Mortality is high especially with ad-
vanced age, prolonged surgical procedures, and
the presence of CPD for patients on warfarin. It is
recommended that there should be a close and strict
follow-up with these patients.
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